| 07/15/08 |
Pro-Pharmaceuticals Has Requested a Pre-IND Meeting with the U.S. Food and Drug Administration.
Introduction of Oxygen-based Product (EZ-646) to the Company’s Galactomannan-C (DAVANAT®) with 5-FU to Treat All Solid Tumors, especially Head & Neck, Breast & Colorectal.
This Study is in Addition to the Company’s Ongoing Phase ll Clinical Trials of DAVANAT® with 5-FU to Treat Colorectal & Biliary Cancer.
|
| 07/11/08 |
Pro-Pharmaceuticals' Senior Executives to Be Featured on PBS' "Wealth & Wisdom".
Financial Television Program to Air the Exclusive Interview.
|
| 07/10/08 |
Pro-Pharmaceuticals Appoints Noted Pioneer in Liver Diseases, Scott L. Friedman, M.D., to Scientific Advisory Board.
Current Chief of the Division of Liver Diseases at Mount Sinai School of Medicine and President-elect of the American Association for the Study of Liver Diseases.
|
| 07/09/08 |
Pro-Pharmaceuticals and Sanghyon Chemical Ink Historic Agency Agreement.
Korean Food & Drug Administration Registration of Lead Compound Candidate DAVANAT® in Korea.
Sales & Marketing Support with Licensing & Distribution Plans.
|
| 06/25/08 |
Pro-Pharmaceuticals' Executives Contribute to Definitive Book on Galectins.
Pro-Pharmaceuticals’ DAVANAT® Targets Galectin Receptorson Cancer Cells. |
| 05/21/08 |
Pro-Pharmaceuticals Issues Letter to Shareholders. |
| 05/20/08 |
Pro-Pharmaceuticals Announces Submission of Drug Master File for DAVANAT® to FDA.
Company Completes an Important Step in NDA Plan for DAVANAT®. |
| 05/20/08 |
Pro-Pharmaceuticals Receives Amex Non-Compliance Notice. |
| 05/19/08 |
Pro-Pharmaceuticals Collaborates with Biocancell Therapeutics to Deliver siRNA Through IV Administration.
DAVANAT® and BC-819 Target Cancer Cells. |
| 05/15/08 |
Pro-Pharmaceuticals Reports First Quarter Results. |
| 05/01/08 |
PRO-PHARMACEUTICALS UPDATES NDA FILING FOR DAVANAT®.
Follows FDA Guidance to Provide Chemistry, Manufacturing & Controls Data. |
| 04/14/08 |
Pro-Pharmaceuticals Announces Change in Auditors. |
| 04/07/08 |
Pro-Pharmaceuticals Announces Commercialization Plans For DAVANAT® With YIACO Medical.
YIACO Medical Represents 80 Health Care Companies and Serves 18 Countries with a Population of 400 Million. |
| 03/28/08 |
Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results.
The Company Plans to File a New Drug Application with the FDA for DAVANAT®. |
| 03/24/08 |
Pro-Pharmaceuticals Announces DAVANAT® Regimen Approved to Treat Breast Cancer Patient. |
| 03/03/08 |
Pro-Pharmaceuticals
DAVANAT® Extends Median Survival 6.7 Months for
End-Stage Colorectal Cancer Patients After All Other
Treatments Failed. |
| 02/28/08 |
Pro-Pharmaceuticals
Closes Financing. |
| 02/15/08 |
Pro-Pharmaceuticals
Enters into Definitive Agreements for $3.775 Million
Financing. |
| 02/11/08 |
New
Data Shows DAVANAT® Extends Survival of End-Stage
Colorectal Cancer Patients More Than 6 Months.
Pro-Pharmaceuticals Tracks Patients After Phase ll
Trial: Two Patients Survived More Than 2 Years.
|
| 02/08/08 |
Pro
Pharmaceuticals Teams With UMass-Lowell On Target
Drug Therapy.
source:
Nanowerk
News
The
Daily Collegian (Matt Sheehan) |
| 02/06/08 |
Pro-Pharmaceuticals
Notes That Shelf Registration is Effective. |
| 01/31/08 |
Pro-Pharmaceuticals
to Present Corporate Update at Russ Trading Investor
Meeting in Tempe, Arizona, and Red Chip Small Cap
Conference in Scottsdale. |
| 01/29/08 |
Pro-Pharmaceuticals
Phase ll Trial Shows DAVANAT® Improves Median
Progression Free Survival with Fewer Side Effects
as Compared to Recent Similar Studies. |
| 01/29/08 |
Pro-Pharmaceuticals
Files $10 Million Shelf Registration. |
| 12/28/07 |
Pro-Pharmaceuticals
Plans to Present a Corporate Update at the Red Chip
Small Cap Investor Conference. |
| 12/19/07 |
Pro-Pharmaceuticals
Selects SAFC®, a Division of SIGMA- ALDRICH™,
to Submit a Drug Master File.
An Important Step in the NDA Approval Process for
DAVANAT®. |
| 12/12/07 |
Pro-Pharmaceuticals
Enters Research Collaboration with University of Massachusetts
Lowell. |
| 12/06/07 |
Pro-Pharmaceuticals
& Brigham and Women's Hospital Announce New Kidney
Fibrosis Research Collaboration. |
| 11/14/07 |
Pro-Pharmaceuticals
Reports Third Quarter Results. |
| 10/30/07 |
Pro-Pharmaceuticals
to Present:
“Advancing Drugs Through Glycoscience®”
at Rodman & Renshaw’s Healthcare Conference.
|
| 10/17/07 |
Pro-Pharmaceuticals
Novel Carbohydrate Compounds Reverse Liver Fibrosis
in Pre-clinical Studies. |
| 10/11/07 |
Pro-Pharmaceuticals
Reports 43% Response Rate in Colorectal Trial; No
Hematological or Gastrointestinal Serious Adverse
Events Reported. |
| 10/02/07 |
Pro-Pharmaceuticals
Names Anthony Squeglia Chief Financial Officer; Steven
Schubert Vice President Finance.
|
| 09/24/07 |
Pro-Pharmaceuticals
Names Theodore Zucconi, Ph.D., President; Nominated
to the Board of Directors.
|
| 09/14/07 |
Amex
Accepts Pro-Pharmaceuticals Plan of Compliance. |
| 08/20/07 |
Pro-Pharmaceuticals’
Sponsored Symposium on Galectins Begins Today as Part
of the American Chemical Society’s 234th Annual
Meeting & Exposition.
Proposed Mechanism of Action for the Company’s
Lead Compound DAVANAT®: Targets Galectin Receptors
on Cancer Cells. |
| 08/16/07 |
Pro-Pharmaceuticals
Announces “Compassionate Use” IND for
DANANAT® to Treat Biliary Cancer Patient. |
| 08/10/07 |
Pro-Pharmaceuticals
Reports Second Quarter Results. |
| 08/03/07 |
Pro-Pharmaceuticals
Retains Camargo Pharmaceutical to Provide Strategic
Regulatory Support for 505(b)(2) Submissions.
|
| 07/27/07 |
Pro-Pharmaceuticals
Issues Corporate Update.
|
| 07/25/07 |
Pro-Pharmaceuticals
Announces Boston Medical Center Dosing Patients with
DAVANAT® in Advanced Biliary Cancer Trial.
|
| 07/24/07 |
Pro-Pharmaceuticals
Submits Plan of Compliance to Amex.
|
| 07/23/07 |
Pro-Pharmaceuticals
Enters Research Agreement with Global Bio-pharmaceutical
Company.
|
| 07/09/07 |
Pro-Pharmaceuticals
Updates Progress
Of Clinical Trials & DAVANAT® 505 (B)(2) Filings.
Phase ll Colorectal Cancer Patients Stabilized Up
to 7 Months; Phase ll Biliary Cancer Patients Stabilized
Up to 5 Months.
Patients Experience No Increase in Drug-Related Toxicity
& Reduced Side Effects with Increased Exposure
to 5-FU & AVASTIN®.
Plans to Submit Manufacturing Data for DAVANAT®
505 (b)(2) Filings to the FDA this Year; No Additional
Toxicity or Clinical Trial Data Needed. |
| 07/02/07 |
Pro-Pharmaceuticals
Terminates Financing Agreement.
The Company is Evaluating other Financing Alternatives.
|
| 06/26/07 |
Pro-Pharmaceuticals
Reports Receipt of Notice from Amex.
|
| 06/19/07 |
Pro-Pharmaceuticals
Enters into Definitive Agreements for a $2.7 Million
Financing.
|
| 06/14/07 |
Pro-Pharmaceuticals
to Sponsor American Chemical Society’s Special
Symposium on Galectins.
Proposed Mechanism of Action for the Company’s
Lead Compound DAVANAT®: Binds to Galectin Receptors
on Cancer Cells.
|
| 06/11/07 |
Pro-Pharmaceuticals
Submits Data to Begin a
505 (b)(2) Filing with the FDA for a New Formulation
of Irinotecan to be Co-administered with DAVANAT®
as a Functional Excipien.
Irinotecan is a Leading Chemotherapy Drug in Colorectal
Cancer Treatment. |
| 05/17/07 |
Pro-Pharmaceuticals
to Present Abstract at the International Society of
Oncodevelopmental Biology and Medicine Conference. |
| 05/15/07 |
Pro-Pharmaceuticals
Reports First Quarter Results. |
| 05/14/07 |
Pro-Pharmaceuticals
Issues Clinical Trial Update. |
| 05/08/07 |
Pro-Pharmaceuticals
to Present and Webcast
at Rodman & Renshaw’s Global Healthcare
Conference.
|
| 04/30/07 |
Pro-Pharmaceuticals
and Digna Biotech Sign Agreement to Apply DAVANAT®
with Novel Drugs to treat Hepatitis C. |
| 04/17/07 |
Pro-Pharmaceuticals
Issues Corporate Update. |
| 04/16/07 |
S.
Colin Neill Nominated to Pro-Pharmaceuticals Board
of Directors. |
| 04/12/07 |
Pro-Pharmaceuticals
Plans to Submit a New Drug Application for DAVANAT®,
as a Functional Excipient, with 5-FU to Treat Cancer. |
| 04/11/07 |
Pro-Pharmaceuticals
Receives Letter from the FDA for New Drug Application
for DAVANAT®/ 5-FU.
FDA
Considers DAVANAT® a “Novel” Excipient.
|
| 04/04/07 |
Pro-Pharmaceuticals
Announces Tampa General Hospital Dosing Patients with
DAVANAT®/5-FU in Phase II, First Line, Advanced
Biliary Cancer Clinical Trial. |
| 04/02/07 |
Pro-Pharmaceuticals
Reports Fourth Quarter and Full Year 2006 Financial
Results.
Annual Shareholders Meeting Scheduled for May 24th. |
| 03/21/07 |
Pro-Pharmaceuticals
Restructures Convertible Debentures. |
| 02/28/07 |
Pro-Pharmaceuticals
Submits Orphan Drug Status Application to European
Medicines Agency.
Co-administration of DAVANAT® with 5-FU to Treat
Cholangiocarcinoma. |
| 02/27/07 |
Pro-Pharmaceuticals
Announces Third Site Dosing Patients with DAVANAT®
in Phase ll, First Line, Colorectal Cancer Clinical
Trial. |
| 02/23/07 |
Pro-Pharmaceuticals
Meeting Scheduled with the FDA.
April 11th Meeting to Discuss NDA Submission for Co-administration
of DAVANAT® with 5-FU to Treat Cancer Patients.
|
| 02/20/07 |
Pro-Pharmaceuticals
Collaborates with Chemwerth to Scale Up Production
of DAVANAT® for Initial Marketing Needs.
Chemwerth Scales Up DAVANAT® to 100 Kilos per
Batch. |
| 02/16/07 |
Pro-Pharmaceuticals
to Account for Warrants as Liabilities from 2003 and
2004 Equity Finance Transactions.
Liability Treatment Does Not Change Operating Expenses
or Cash Position. |
| 02/12/07 |
Pro-Pharmaceuticals
Requests Meeting with the FDA to Discuss New Drug
Application for
Co-administration of DAVANAT® with 5-FU to Treat
Cancer Patients.
5-FU is one of the most widely used chemotherapy drugs
in the world. |
| 02/07/07 |
Pro-Pharmaceuticals’
Begins Process of New Drug Application Submission
with the FDA for Co-administration of DAVANAT®
with 5-FU
in Cancer Patients. |
| 01/23/07 |
Pro-Pharmaceuticals
Announces Dosing of Patients with DAVANAT® in
Phase II, First Line, Advanced Biliary Cancer Clinical
Trial. |
| 12/22/06 |
Pro-Pharmaceuticals
Provides Corporate Update of 2006 Achievements and
2007 Objectives. |
| 12/20/06 |
Pro-Pharmaceuticals
Appoints Dr. James Gourzis to its Board of Directors. |
| 12/19/06 |
Pro-Pharmaceuticals
Signs Agreement with CESAR to Expand Recruitment of
Patients for the Phase ll Biliary Cancer Trial. |
| 11/27/06 |
Pro-Pharmaceuticals
Announces Dosing of Patients with DAVANAT® in
Phase II, First Line, Colorectal Cancer Clinical Trial. |
| 11/21/06 |
Rodman
& Renshaw, LLC Initiates Research Coverage on
Pro-Pharmaceuticals. |
| 11/13/06 |
Pro-Pharmaceuticals
Reports Third Quarter 2006 Results. |
| 11/01/06 |
Pro-Pharmaceuticals
to Present a Corporate Update at Rodman & Renshaw
Healthcare Conference; ''Advancing Drugs Through Glycoscience''
Presentation to be Webcast.
|
| 10/30/06 |
Pro-Pharmaceuticals
to Present a Corporate Update at MASS Opps: a Biotechnology
Investment Conference. |
| 10/17/06 |
Pro-Pharmaceuticals
to Present at BIO Investor Forum. |
| 09/28/06 |
Pro-Pharmaceuticals
Announces Cash Payment of Debentures & Clinical
Trial Progress. |
| 08/30/06 |
Pro-Pharmaceuticals
Updates Clinical Trials Progress. |
| 08/14/06 |
Pro-Pharmaceuticals
Reports Second Quarter 2006 Results. |
| 07/25/06 |
Pro-Pharmaceuticals
Files Phase II Clinical Trial Protocol for First Line
Treatment of Colorectal Cancer Patients.
Regimen Includes DAVANAT® with Avastin(R), 5-FU
& Leucovorin. |
| 06/05/06 |
Pro-Pharmaceuticals'
Abstract Published in ASCO Annual Meeting Proceedings.
Company Provides Clinical Trial Update. |
| 05/31/06 |
Pro-Pharmaceuticals'
Executives Contribute to New Book ''Carbohydrate Drug
Design'' Published by American Chemical Society. |
| 05/24/06 |
Pro-Pharmaceuticals
& Mount Sinai School of Medicine Announce New
Liver Fibrosis Research Collaboration. |
| 05/22/06 |
Pro-Pharmaceuticals
Reports First Quarter 2006 Financial Results.
Annual Shareholders Meeting Scheduled for May 25th. |
| 05/09/06 |
Pro-Pharmaceuticals
to Present Corporate Update at Rodman & Renshaw
Global Healthcare Conference.
''Advancing Drugs Through Nanotechnology Glycoscience''
Presentation to be Available via Webcast. |
| 05/08/06 |
Pro-Pharmaceuticals
Retains Dr. James T. Gourzis to Provide Clinical Management
& Strategic Development of Its Europe-Based Phase
III Colorectal Cancer Trial. |
| 04/10/06 |
Dr.
Henry Esber Nominated to Pro-Pharmaceuticals Board
Of Directors. |
| 04/07/06 |
Pro-Pharmaceuticals'
CEO to Present Corporate Update at BIO Annual Convention. |
| 04/05/06 |
Pro-Pharmaceuticals
Reports Preliminary Data Shows an Objective Partial
Tumor Response in Phase II Colorectal Cancer Trial
Evaluating DAVANAT® with 5-FU. |
| 03/30/06 |
Pro-Pharmaceuticals
Completes Patient Enrollment in Stage 1 of Phase II
Colorectal Cancer Trial Evaluating DAVANAT® with
5-FU. |
| 03/23/06 |
Pro-Pharmaceuticals
to Present Corporate Update at Russ Trading Hosted
Event in Scottsdale, Arizona. |
| 03/22/06 |
Pro-Pharmaceuticals
Featured on ''American Scene'' Financial Talk Radio
Show. |
| 03/17/06 |
Pro-Pharmaceuticals'
Abstract Accepted for Publication in ASCO Annual Meeting
Proceedings. |
| 03/16/06 |
Pro-Pharmaceuticals
Continues to Strengthen
Intellectual Property Portfolio.
Fifth U.S. Patent Covers Co-administration of a Carbohydrate
with a Chemotherapy Agent to Treat Cancer. |
| 03/14/06 |
Pro-Pharmaceuticals'
CEO Featured on Wall Street Reporter. |
| 03/10/06 |
Pro-Pharmaceuticals
Reports Unaudited Fourth Quarter and Full Year 2005
Financial Results.
|
| 03/02/06 |
Pro-Pharmaceuticals
to Present Abstract & Poster at Mass Biotechnology
Council Discovery Day Symposium.
|
| 02/24/06 |
Pro-Pharmaceuticals
Presents Phase II/III Clinical Trials at the Central
European Society for Anti-Cancer Drug Research Conference. |
| 02/15/06 |
Pro-Pharmaceuticals
Announces $10 Million Financing. |
| 02/02/06 |
Pro-Pharmaceuticals
Receives 'Compassionate Use' IND for Use of DAVANAT®/5-FU
to Treat Another Patient with Cholangiocarcinoma. |
| 01/23/06 |
Scientist’s
passion for pharmaceutical innovation driving cancer
drug trials. |
| 01/13/06 |
Pro-Pharmaceuticals
Announces the Appointment of Anatole Klyosov, Ph.D.,
D.Sc. as Chief Scientist.
Company Continues to Strengthen Intellectual Property
Portfolio—Receives New U.S. Patent for the Delivery
of a Therapeutic Agent to Reduce Toxicity. |
| 12/13/05 |
Pro-Pharmaceuticals
Announces Two International Clinical Sites in Colorectal
Cancer Trial of DAVANAT®/5-FU. |
| 12/09/05 |
Pro-Pharmaceuticals
Issues Corporate Update.
Outlines Achievements and Key Clinical Milestones.
|
| 11/11/05 |
Pro-Pharmaceuticals
to Present at Annual Glycobiology Conference.
Targeting Tumor Lectins, DAVANAT® Shows Promising
Results in Phase I Trial with 5-FU Refractory Patients.
|
| 11/10/05 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 11/07/05 |
Pro-Pharmaceuticals
Receives Clearance from EMEA to Initiate International
Phase III Colorectal Cancer Clinical Trial. |
| 11/02/05 |
Pro-Pharmaceuticals
to Present at Techvest Healthcare Conference. |
| 10/25/05 |
Pro-Pharmaceuticals
to Present at Mass Opps
Biotech Investor Conference. |
| 10/14/05 |
Pro-Pharmaceuticals
Reports Enrollment Progress in Phase II Colorectal
Cancer Trial with DAVANAT®/5-FU. |
| 10/06/05 |
Pro-Pharmaceuticals
Announces Final Phase I Results.
Pharmacokinetics Analysis Indicates 5-FU, in Combination
with DAVANAT®, Remains Significantly Longer in
the Bloodstream of Cancer Patients, Potentially Increasing
5-FU’s Efficacy while Lowering Toxicity.
|
| 09/20/05 |
Pro-Pharmaceuticals
to Present New DAVANAT® Data at the International
Society of Oncodevelopmental Biology and Medicine
Conference.
|
| 09/13/05 |
Pro-Pharmaceuticals
Files Phase ll Protocol for DAVANAT®/5-FU in First
Line Cholangiocarcinoma Study.
“Compassionate Use” Patient Continues
to Respond Well after 10 Months of Treatment with
DAVANAT®/5-FU. |
| 08/25/05 |
Pro-Pharmaceuticals
Announces Dosing of Patient with DAVANAT®/5-FU
in Phase II Colorectal Cancer Trial at Ochsner Cancer
Institute. |
| 08/05/05 |
Pro-Pharmaceuticals
Reports Second Quarter Results. |
| 07/28/05 |
Pro-Pharmaceuticals
Announces Termination of SEC Investigation. |
| 07/21/05 |
Vista
Partners Initiates Research Coverage of Pro-Pharmaceuticals.
|
| 07/07/05 |
Pro-Pharmaceuticals
Receives New U.S. Patent for the Delivery of a Chemotherapeutic
Agent to Reduce Toxicity.
New Patent Strengthens the Company’s Intellectual
Property Portfolio. |
| 06/27/05 |
PRO-PHARMACEUTICALS
ADDED TO THE NEW RUSSELL MICROCAP INDEX. |
| 05/19/05 |
PRO-PHARMACEUTICALS
ANNOUNCES DOSING OF CANCER PATIENT with DAVANAT®/5-FU
in a PHASE II CLINICAL TRIAL at HEMATOLOGY-ONCOLOGY
ASSOCIATES of TREASURE COAST |
| 05/17/05 |
PRO-PHARMACEUTICALS’
PHASE II COLORECTAL CANCER TRIAL OF
DAVANAT®/5-FU POSTED TO CLINICAL TRIALS.GOV WEBSITE
Metastatic Colorectal Cancer Trial is Recruiting Patients
for Third- or Fourth-Line Therapy |
| 05/16/05 |
PRO-PHARMACEUTICALS’
PHASE I DATA SHOW DAVANAT®/5-FU WELL-TOLERATED IN
CANCER PATIENTS WITH ADVANCED SOLID TUMORS
Disease Stabilized in 54% of Patients with Measurable
Disease; 60% Stabilized at Highest Dose Level; 71% Received
Additional Cycles |
| 05/13/05 |
Pro-Pharmaceuticals
Reports First Quarter Results |
| 05/12/05 |
PRO-PHARMACEUTICALS
RECEIVES “COMPASSIONATE USE” IND FOR USE
OF DAVANAT®/5-FU WITH A PATIENT WHO HAS CHOLANGIOCARCINOMA
WITH LIVER METASTASES |
| 05/09/05 |
PRO-PHARMACEUTICALS
ANNOUNCES DOSING OF CANCER PATIENT with DAVANAT®/5-FU
in a PHASE II CLINICAL TRIAL at MEDICAL ONCOLOGY &
HEMATOLOGY, P.C. |
| 05/02/05 |
Pro-Pharmaceuticals
to Present at Techvest Global Healthcare Conference |
| 04/27/05 |
Research
Analyst Report on Pro-Pharmaceutials |
| 04/08/05 |
Pro-Pharmaceuticals
Reports Fourth Quarter and Full Year 2004 Results
Annual Shareholders Meeting Scheduled for May 25th |
| 03/22/05 |
Pro-Pharmaceuticals’
Lead Compound DAVANAT® Enhances Anti-Tumor Activity
of Avastin™/5-FU in Pre-Clinical Studies
Data Presented at Glycomics & Carbohydrates Conference
|
| 03/03/05 |
PRO-PHARMACEUTICALS’
FINAL PHASE l ABSTRACT ACCEPTED FOR PUBLICATION IN ASCO
ANNUAL MEETING PROCEEDINGS |
| 02/24/05 |
PRO-PHARMACEUTICALS
ENGAGES WORLDCARE CLINICAL TO ENHANCE AND ACCELERATE
THE PHASE II TRIAL |
| 02/14/05 |
PRO-PHARMACEUTICALS
POSTS ASCO DATA TO ITS WEBSITE
DAVANAT®/5-FU Well Tolerated; Dose Limiting Toxicity
Not Reached; Disease Stabilized in 45% of Patients |
| 02/11/05 |
PRO-PHARMACEUTICALS
NAMES CARL LUEDERS CHIEF FINANCIAL OFFICER |
| 01/27/05 |
PRO-PHARMACEUTICALS’
ASCO DATA SHOW DAVANAT®/5-FU WELL-TOLERATED IN PATIENTS
WITH ADVANCED CANCER
Disease Stabilized in 45% of Patients who Completed
Study through November |
| 01/17/05 |
PRO-PHARMACEUTICALS
COMPLETES ENROLLMENT IN PHASE I TRIAL OF DAVANAT®/5-FU
IN REFRACTORY CANCER PATIENTS |
| 12/14/04 |
PRO-PHARMACEUTICALS’
DAVANAT®/5-FU PHASE l TRIAL DATA TO BE PRESENTED
AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM |
| 11/30/04 |
Pro-Pharmaceuticals
Responds to The Boston Globe Article |
| 11/22/04 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 11/18/04 |
Pro-Pharmaceuticals
'Sets the Record Straight' Regarding Misleading Statements
Made by GlycoGenesys in News Releases |
| 11/12/04 |
Dr.
David Platt Gratified with Arbitrator's Decision: Continues
to Control Prosecution of Modified Pectin Patent Applications |
| 11/08/04 |
PRO-PHARMACEUTICALS
TO PRESENT CORPORATE UPDATE AT BIO-EUROPE 2004 INTERNATIONAL
PARTNERING CONFERENCE |
| 11/03/04 |
PRO-PHARMACEUTICALS
TO PRESENT AT MASS OPPORTUNITIES BIOTECHNOLOGY CONFERENCE |
| 10/21/04 |
PRO-PHARMACEUTICALS
TO PRESENT
AT TECHVEST ANNUAL HEALTHCARE CONFERENCE |
| 10/13/04 |
PRO-PHARMACEUTICALS
TO PRESENT
AT BIO EMERGING COMPANY INVESTOR FORUM |
| 10/04/04 |
PRO-PHARMACEUTICALS
PROVIDES PHASE I TRIAL UPDATE OF DAVANAT® IN REFRACTORY
CANCER PATIENTS |
| 09/30/04 |
PRO-PHARMACEUTICALS
APPOINTS MEDICAL ADVISORY BOARD MEMBERS |
| 09/28/04 |
PRO-PHARMACEUTICALS
RETAINS HANIFY & KING’S LIFE SCIENCES GROUP
TO PURSUE COLLABORATIONS |
| 08/19/04 |
Pro-Pharmaceuticals'
CEO David Platt Granted Patents for Modified Pectin
Material in European Union, Canada, Australia &
New Zealand |
| 08/12/04 |
Pro-Pharmaceuticals
Raises $6 Million |
| 06/23/04 |
PRO-PHARMACEUTICALS
REPORTS PHASE I FOR DAVANAT®-1 IN REFRACTORY CANCER
PATIENTS IS NOW IN ITS SIXTH AND FINAL COHORT |
| 04/07/04 |
Pro-Pharmaceuticals
Raises $4.5 Million |
| 03/24/04 |
Pro-Pharmaceuticals
to Present at Company-Sponsored Carbohydrate Drug Design
Symposium During National Meeting of the American Chemical
Society |
| 03/12/04 |
Pro-Pharmaceuticals
Appoints Jerald K. Rome to Board of Directors |
| 02/25/04 |
Dr.
David Platt and Pro-Pharmaceuticals to Vigorously Contest
Counterclaims Asserted by GlycoGenesys |
| 01/08/04 |
Pro-Pharmaceuticals
to Initiate a Phase II Clinical Trial of its Lead Anti-Tumor
Compound DAVANAT® + 5-FU in Colorectal Cancer |
| 12/17/03 |
Pro-Pharmaceuticals
Names Charles Harney Chief Financial Officer |
| 12/09/03 |
Pro-Pharmaceuticals
Announces the Dosing of Cancer Patients at Florida Oncology
Associates |
| 11/13/03 |
Pro-Pharmaceuticals
Issued Two U.S. Patents for its Core Carbohydrate Drug
Targeting & Delivery Platforms -- CARBOSOME™
& UCLT™ |
| 10/28/03 |
Mass
Opportunities: A Biotechnology Investment Conference,
October 28, 11:30 AM, The Hilton Logan Airport, Boston |
| 10/15/03 |
Pro-Pharmaceuticals
To Present: `Advancing Drugs Through Glycoscience' at
Techvest Healthcare & MassOpps Investment Conferences |
| 10/3/03 |
Pro-Pharmaceuticals
Announces $4.6 Million Private Placement Financing |
| 9/22/03 |
Pro-Pharmaceuticals
rang the opening bell on the American Stock Exchange |
| 9/16/03 |
Animal
Studies Demonstrate the Importance Pro-Pharmaceuticals’
DAVANAT® Played in Significantly Increasing the
Anti-Cancer Efficacy of 5-Fluorouracil |
| 9/15/03 |
Pro-Pharmaceuticals
To Present: Advancing Drugs Through Glycoscience™
at UBS “Global Life Sciences” & Burrill
“Life Sciences Partnering” Conferences |
| 9/10/03 |
American
Stock Exchange Lists Common Stock of Pro-Pharmaceuticals,
Inc. |
| 9/10/03 |
Pro-Pharmaceuticals’
CEO Chairs “Cancer Drugs 2003” Conference |
| 9/10/03 |
Pro-Pharmaceuticals’
Common Stock Begins Trading Today on AMEX® Under
the Symbol “PRW” |
| 9/9/03 |
Pro-Pharmaceuticals’
Common Stock to be Traded on AMEX® Under the Symbol
“PRW” |
| 7/21/03 |
Pro-Pharmaceuticals
Appoints Noted Carbohydrate Chemist Zbigniew J. Witczak,
Ph.D. to Its Scientific Advisory Board |
| 7/15/03 |
Pro-Pharmaceuticals
To Host Corporate Presentations in Denver, Austin &
Chicago |
| 7/2/03 |
Pro-Pharmaceuticals
Announces Publication of Study in Peer-Reviewed Journal
Carbohydrate Research |
| 6/24/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals’ DAVANAT®
in Phase I Clinical Trial at the Norris Cotton Cancer
Center
at Dartmouth-Hitchcock Medical |
| 6/20/03 |
Pro-Pharmaceuticals
To Host Corporate Presentations |
| 5/29/03 |
Pro-Pharmaceuticals
Names Squeglia VP Investor Relations |
| 5/14/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals’ DAVANAT®
in Phase I Clinical Trial at the Ochsner Cancer Institute |
| 4/28/03 |
Pro-Pharmaceuticals
Receives Patent Allowance for Its Carbohydrate Linker
Technology for Anti-Cancer Agents |
| 4/14/03 |
Pro-Pharmaceuticals
Appoints Steven Prelack to Board of Directors |
| 4/3/03 |
Pro-Pharmaceuticals
Reports Year End Results |
| 3/20/03 |
Pro-Pharmaceuticals
Appoints David Christopher as CFO |
| 2/14/03 |
Cancer
Patients Injected With Pro-Pharmaceuticals' DAVANAT®
in Phase I Clinical Trial At Howell, New Jersey Oncology
Clinics |
| 2/6/03 |
Pro-Pharmaceuticals
Initiates Multi-Center Clinical Trials Of DAVANAT®-1
For All Solid Tumors |
| 1/15/03 |
Pro-Pharmaceuticals
Completes Private Placement |
| 1/6/03 |
Pro-Pharmaceuticals
Expands Clinical Cancer Trial to Include Additional
Solid Tumors |
| 12/30/02 |
Pro-Pharmaceuticals
Engages Medidata for Real-Time Electronic Data Collection
in its Clinical Cancer Trial |
| 12/19/02 |
Pro-Pharmaceuticals
Retains PRA International for Clinical Trial In Cancer
Patients |
| 12/10/02 |
Pro-Pharmaceuticals
Presents Overview of Carbohydrate Technology To Enhance
Existing Cancer Drugs |
| 11/15/02 |
Pro-Pharmaceuticals
Reports Third Quarter Results |
| 10/22/02 |
Pro-Pharmaceuticals
Names Medical Director for Upcoming Clinical Study.
Marilyn Pike engaged as clinical development consultant
to oversee firm's Phase I drug trial |
| 10/7/02 |
Pro-Pharmaceuticals
Appoints Mildred Christian to Board of Directors.
Expert on experimental design and government compliance
to serve multiple roles with firm |
| 9/25/02 |
Pro-Pharmaceuticals
Featured in ‘Genetic Engineering News’ Overview
of
Innovative Cancer Therapy Research |
| 9/12/02 |
Pro-Pharmaceuticals Names University of Michigan Medical
School Professor to Scientific Advisory Board. Expert
on specialized protein-carbohydrate chemistry to consult
on upcoming clinical trials. |
| 9/5/02 |
Pro-Pharmaceuticals
Commences Trading on NASD OTC Bulletin Board. Trading
Follows FDA Approval of Human Trials With Cancer Drug
Enhancement Formulation. |
| 8/26/02 |
Pro-Pharmaceuticals
Reports Second Quarter Results |
| 7/29/02 |
Pro-Pharmaceuticals
Receives FDA Approval for Phase I Clinical Trial |
| 7/11/02 |
Pro-Pharmaceuticals
Announces Public Reporting of Financial Results |
